Research and Development

Japanese pharmaceutical company Astellas and US-based clinical-stage biopharmaceutical company Cullgen have announced that they have entered into a strategic research …

US-based Critical Path Institute (C-Path) has announced that the Biomarker Qualification Program (BQP) at the Center for Drug Evaluation and …

US clinical-stage biopharmaceutical company Kymera Therapeutics has shared new data regarding its oncology programmes KT-333 and KT-413, highlighting their robust dose-dependent …

Canadian biotechnology company PharmAla has announced that it has been awarded a research grant from the Ontario Centre of Innovation …

UK-based pharmaceutical company AstraZeneca has announced that the National Institute for Health and Care Excellence (NICE) posted a positive recommendation …

Japanese pharmaceutical company Astellas Pharma and the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) have presented their phase …

Innate Pharma has announced that the drug jointly researched between itself and Sanofi has received US Food and Drug Administration (FDA) …

Pluripotent stem cell technology provider Axol Bioscience has signed an exclusive agreement with UK-based StrataStem to access and commercialise its …

The UK Government has announced plans to launch a pilot programme which will provide GPs with Novo Nordisk’s Wegovy (semaglutide), …

US-based healthcare company GRAIL and the University of Oxford, UK, have announced encouraging first prospective study results at the American …

Clinical stage biotechnology company ISA Pharmaceuticals has announced positive phase 1 data at the American Society of Clinical Oncology (ASCO) …

GSK has announced that the US Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for …

AstraZeneca has announced that its post-marketing phase 4 ANNEXA-I trial has been stopped early after reaching its pre-specified stopping criteria. …

Allogene Therapeutics has shared updated data from the phase 1 ALPHA/ALPHA2 trials of ALLO-501/501A in patients with relapsed/refractory (r/r) large …

Swedish clinical stage biotech company BioInvent has announced that it has received Investigational New Drug (IND) approval for its monoclonal …